– USA, CA – Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointments of Dr. Stacey Ma, EVP, and Head of Technical Operations at Sana Biotechnology, and Steve Brady, CEO of Tempest Therapeutics, to its Board of Directors.
“We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives” said CEO, John Orwin. “Together, Stacey and Steve bring over 40 years of industry experience across a variety of corporate functions, including research, technical operations, manufacturing, corporate development and finance. Their expertise will be invaluable to Atreca as we continue to advance ATRC-101 and build our preclinical pipeline.”
About Dr. Stacey Ma
Dr. Ma is currently the EVP and Head of Technical Operations at Sana Biotechnology, a publicly listed biotechnology company, where she has served since March 2019. From 1996 to 2019, she served various roles at Genentech/Roche, a biotechnology company, including as their Global Head of Innovation, Manufacturing Science and Technology from March 2018 to March 2019, and as VP, Global Head of Investigational Medicinal Products Quality from May 2015 to February 2018. From July 1996 to May 2015, she held various other roles related to analytical development, pharmaceutical development, quality, technical product management, and supply chain.
About Steve Brad
Mr. Brady is currently CEO of Tempest Therapeutics, a publicly listed biotechnology company. Previously, he served as the President and COO at Tempest from September 2019 to June 2021. Before joining Tempest, he served in various leadership roles at Immune Design Corp., including as EVP, Strategy & Finance from May 2015 until its sale to Merck in 2019, and as Chief Business Officer from September 2013 to May 2015. Before Immune Design, Mr. Brady served in various leadership roles at 3-V Biosciences, Inc., including as Chief Business Officer from February 2011 to August 2013, and as VP, Corporate Development, Strategy, and Operations from February 2010 to February 2011. From April 2007 to March 2010, Mr. Brady held various roles at Proteolix, Inc., most recently serving as VP of Corporate Development.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
For more information: https://www.atreca.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
